Tokai Pharmaceuticals to Present New Galeterone Mechanism of Action Data at 2013 American Society of Clinical Oncology GU  
2/15/2013 9:33:37 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that new preclinical data demonstrating the differentiated potent and selective CYP17 lyase inhibition mechanism of action of its lead candidate, galeterone (TOK-001), will be presented today in a poster presentation titled, “Galeterone, Abiraterone, Orteronel and Ketoconazole Exhibit Differential Inhibitory Effects on CYP17 and Steroidogenesis,” abstract number 184, at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in Orlando, Fla.